DISTINCT IMMUNE AND TRANSCRIPTOMIC PROGRAMS UNDERLIE ESA RESPONSE ACCORDING TO TIMING OF INITIATION IN LOWER-RISK MDS: CORRELATIVE BIOLOGICAL RESULTS OF THE EPO-PRETAR TRIAL

EHA Library, Sophie Park, 4208293

CHARACTERIZATION AND MECHANISM OF T CELL EXHAUSTION IN THE BONE MARROW IMMUNE MICROENVIRONMENT OF MYELODYSPLASTIC NEOPLASMS PATIENTS WITH TP53 MUTATIONS

EHA Library, Lingxu Jiang, 4208295

MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGULATING MITOCHONDRIA OXIDATIVE METABOLIC PATHWAY

EHA Library, Baoxia Dong, 4208300

ASXL1 MUTATIONS ARE A NOVEL RISK FACTOR FOR MAJOR BLEEDING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Elay Amidor, 4208302

ASSOCIATION OF MHC CLASS I POLYPEPTIDE-RELATED SEQUENCE A (MICA) AND B (MICB) ALLELE POLYMORPHISMS WITH SUSCEPTIBILITY TO MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Eleni PORFYRIOU, 4208306

LONGITUDINAL EVALUATION OF CLONAL HEMATOPOIESIS DYNAMICS IN OVARIAN CANCER PATIENTS DURING PARP INHIBITORS TREATMENT

EHA Library, Elisabetta Todisco, 4208307

COEXISTING BUT GENETICALLY DISTINCT HEMATOPOIETIC AND STROMAL ALTERATIONS IN MYELODYSPLASTIC SYNDROMES

EHA Library, María Díez Campelo, 4208309

VEXAS PROGNOSTIC SCORE: PERSONALIZED MACHINE LEARNING DERIVED RISK STRATIFICATION MODEL

EHA Library, Tariq Kewan, 4208310

PHASE II STUDY OF CLADRIBINE, LOW DOSE CYTARABINE AND VENETOCLAX, ALTERNATING WITH AZACITIDINE AND VENETOCLAX, IN HIGHER RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Montalban-Bravo, 4208311

UPDATED PHASE 2 RESULTS OF ELRITERCEPT IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT (TD) LOWER-RISK MYELODYSPLASTIC NEOPLASMS (LR-MDS)

EHA Library, María Díez Campelo, 4208313

A FOUR-GENE STEMNESS SCORE PREDICTS HMA RESISTANCE AND IDENTIFIES RATIONAL 5-AZACITIDINE COMBINATION STRATEGIES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Yu-Hung WANG, 4208314

CLINICAL, GENETIC, AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROME/NEOPLASMS WITH AUTOIMMUNE DISEASES

EHA Library, Tai-Chung Tseng, 4208315

LONG-TERM RISK OF HEMATOLOGIC MALIGNANCIES IN PATIENTS WITH UNEXPLAINED LEUKOPENIA: A 10-YEAR RETROSPECTIVE GLOBAL COHORT STUDY

EHA Library, Ruyi Huang, 4208320

REAL-WORLD EFFECTIVENESS OF LUSPATERCEPT IN TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES: RESULTS FROM THE CZECH MYDYS REGISTRY

EHA Library, Anna Jonášová, 4208322

BORTEZOMIB COMBINED WITH AZACITIDINE AND VENETOCLAX IN HIGH-RISK MYELODYSPLASTIC NEOPLASMS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Zi-Yuan Nie, 4208326

LONGITUDINAL IPSS-M RISK EVALUATION IN 205 MDS PATIENTS: IS REASSESSMENT BEYOND INITIAL DIAGNOSIS NECESSARY?

EHA Library, Anetta Marcinek, 4208327

GENOMIC LANDSCAPE AND SURVIVAL OUTCOMES IN MYELODYSPLASTIC SYNDROMES WITH FIBROSIS: A REAL-WORLD ANALYSIS FOR REFINING THE HIGH-RISK PHENOTYPE IN THE IPSS-M ERA

EHA Library, Arda Bayar, 4208328

REAL-WORLD OUTCOMES OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS: INSIGHTS FROM THE FRENCH EARLY ACCESS PROGRAM.

EHA Library, Régis Peffault de Latour, 4208331

IMMUNE REPERTOIRE SIGNATURE LINKS HEPATITIS AND THE DESTRUCTION OF HAEMATOPOIETIC PRECURSORS IN HEPATITIS-ASSOCIATED APLASTIC ANAEMIA

EHA Library, Daniel Dulla, 4208332

DIAMOND BLACKFAN ANEMIA SYNDROME ERYTHROID PROGENITORS DISPLAY ABNORMAL METABOLOMIC PROFILE

EHA Library, Veronica Riccardi, 4208333

THE ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN THROMBOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Rong Fu, 4208334

DISSOCIATION BETWEEN VISCERAL AND SKELETAL DISEASE IN MILD GENOTYPES OF GAUCHER DISEASE TYPE 1

EHA Library, Irene Serrano-Gonzalo, 4208336

SUSTAINED LONG-TERM REAL-WORLD EFFECTIVENESS AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH PNH: ONGOING COMPLETE PHASE 4 STUDY

EHA Library, Lenka Mastíková, 4208346

TRANSPLANT OUTCOMES FOR PATIENTS WITH SEVERE ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40 USING BUSULFAN, FLUDARABINE, REDUCED-DOSE CYCLOPHOSPHAMIDE, AND ANTI-THYMOCYTE GLOBULIN CONDITIONING REGIMEN.

EHA Library, Fan Lin, 4208347

ANDROGEN TREATMENT FOR TELOMERE BIOLOGY DISORDERS: LONG-TERM RESULTS FROM A RETROSPECTIVE REGISTRY ANALYSIS

EHA Library, Fabian Beier, 4208350

COMPARISON OF EFFICACY BETWEEN INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH UMBILICAL CORD BLOOD THERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SAA AGED OVER 40 YEARS

EHA Library, Fang Zhou, 4208351

IRON OVERLOAD IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS ON C5 - INHIBITORS MAY RESULT FROM ABNORMAL IRON REGULATION IN ADDITION TO INCREASED EXTRAVASCULAR HEMOLYSIS.

EHA Library, Mira Jani, 4208352

CLINICAL CHARACTERISTICS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION PROGNOSIS IN SHWACHMAN-DIAMOND SYNDROME: A REPORT OF 116 CASES FROM A SINGLE CHINISE CENTER

EHA Library, Jiao Chen, 4208353

THROMBOEMBOLISM IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE ERA OF COMPLEMENT INHIBITORS – MULTICENTER ANALYSIS BY THE POLISH ADULT LEUKEMIA GROUP

EHA Library, Agnieszka Piekarska, 4208354

CLINICAL HETEROGENEITY AND LONG-TERM OUTCOMES OF CHILDHOOD AUTOIMMUNE NEUTROPENIA: Α 20-YEAR COHORT STUDY

EHA Library, Alexandros Makis, 4208356

EFFICACY AND SAFETY OF LUSUTROMBOPAG IN PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: RESULTS FROM A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, EXPLORATORY STUDY

EHA Library, Ting Wang, 4208361

A REAL-WORLD STUDY: EFFICACY AND SAFETY OF COMPLEMENT INHIBITORS (ECULIZUMAB OR IPTACOPAN) COMBINED WITH CYCLOSPORINE IN PATIENTS WITH APLASTIC ANEMIA-PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SYNDROME

EHA Library, Guangsheng He, 4208362

LATE AND SUSTAINED RESPONSES TO IMMUNOSUPPRESSIVE THERAPY PLUS ROMIPLOSTIM IN TREATMENT‑NAÏVE APLASTIC ANEMIA

EHA Library, Kohei Hosokawa, 4208364

CLINICAL EFFICACY AND SAFETY OF COMPLEMENT INHIBITOR MONOTHERAPY AND COMBINED IMMUNOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-APLASTIC ANEMIA (PNH-AA): A SINGLE-CENTER COHORT STUDY

EHA Library, Rong Fu, 4208365

IPTACOPAN TREATMENT FOR CHINESE PATIENTS WITH HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Bing Han, 4208366

IRF2 IS AN ESSENTIAL TRANSCRIPTION FACTOR WITH PATHOGENIC AND PROGNOSTIC IMPACT IN MULTIPLE MYELOMA

EHA Library, Nahia Gomez-Echarte, 4208370

IMMUNE EXCLUSION IN EXTRAMEDULLARY MYELOMA VERSUS SOLITARY BONE PLASMACYTOMA DEPICTED VIA IMAGING MASS CYTOMETRY

EHA Library, Maximilian Steinhardt, 4208372

IDENTIFICATION OF PRECURSOR CELLS OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA AND THEIR THERAPEUTIC TARGETS BY INTEGRATED OMICS ANALYSIS

EHA Library, Shojiro Haji, 4208375

STROMAL NANOTUBE NETWORKS PROMOTE TRANSMITOPHAGY AND METABOLIC ADAPTATION IN MULTIPLE MYELOMA

EHA Library, Antonio Solimando, 4208377

AN NGS LIQUID BIOPSY APPROACH FOR GENOMIC CHARACTERIZATION IN MULTIPLE MYELOMA: HEAD-TO-HEAD COMPARISON WITH BONE MARROW FISH

EHA Library, Efstathios Kastritis, 4208380

ACUTE DEGRADATION OF ONCOGENIC MAF IN MYELOMA CELLS REVEALS MAF-DEPENDENT IRF4 CO-BINDING AND REGULATION OF ONCOGENIC TRANSCRIPTIONAL PROGRAMMES.

EHA Library, Qizhen Jia, 4208382

PROGNOSTIC VALUE OF STANDARDIZED QUANTITATIVE FDG PET/CT BIOMARKERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Georg-Michael Krause, 4208384

THERAPY-ASSOCIATED IMMUNE SENESCENCE IN MULTIPLE MYELOMA: A QUANTITATIVE MODEL TO INFORM TIMING OF CELLULAR THERAPY

EHA Library, Ehsan Malek, 4208385

AGE-STRATIFIED ANALYSIS OF CML-CP IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Jian Huang, 4208288

HOW MANY CHRONIC-PHASE CML PATIENTS STARTING TYROSINE KINASE INHIBITORS CAN ACHIEVE A PERSISTENT TREATMENT FREE REMISSION AND BE POTENTIALLY CURED? A SINGLE CENTER REAL-LIFE EXPERIENCE.

EHA Library, Mariella D'Adda, 4208289

THERAPEUTIC STRATEGIES IN ADVANCED OR TKI-REFRACTORY CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS: THE ITALIAN EXPERIENCE

EHA Library, Elisa Quinti, 4208290

MRD-TAILORED TREATMENT WITH DECITABINE COMBINED WITH DASATINIB IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE INDUCTION THERAPY: REAL-WORLD DATA IN RESOURCE-LIMITED SETTING

EHA Library, Uttam Kumar Nath, 4208291

LUSPATERCEPT REDUCES CARDIAC STRESS AND IMPROVES CARDIAC FUNCTION IN TET2-DEFICIENT HFPEF-LIKE MOUSE MODEL: TRANSLATIONAL EVIDENCE FROM PRECLINICAL STUDIES AND PHASE 3 COMMANDS TRIAL

EHA Library, Guillermo Garcia-Manero, 4208292

ORAL HYPOMETHYLATING AGENT NTX-301 DEMONSTRATES POTENT ANTI-LEUKEMIC ACTIVITY AND ENHANCES RESPONSE TO VENETOCLAX IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Arnold Kloos, 4208294

DISTINCT PROGENITOR PROGRAMS DRIVE SUBGROUP-SPECIFIC MECHANISMS OF ANEMIA  IN MYELODYSPLASTIC SYNDROMES

EHA Library, Carmen Rodriguez-Res, 4208296

MACHINE LEARNING UNCOVERS INVARIANT EVOLUTIONARY MOLECULAR TRAJECTORIES IN MDS.

EHA Library, MATTEO D'ADDONA, 4208297

SINGLE-CELL JOINT PROFILING OF GENOTYPES, EPIGENOME, AND TRANSCRIPTOMES IN TET2-MUTANT CLONAL PRE-LEUKEMIC LESIONS

EHA Library, Masanori Motomura, 4208298

DOWN-REGULATION OF THE NFAT/TOX PATHWAY IMPROVES THE T-CELL EXHAUSTION STATE IN THE BONE MARROW OF PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCOMPANIED BY T LARGE GRANULAR LYMPHOCYTE PROLIFERATION

EHA Library, Chenxiao Du, 4208299

AN INTEGRATIVE APPROACH COMBINING SINGLE-CELL DNA-SEQ AND SURFACEOME REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES SPECIFIC TO SOMATIC ABNORMALITIES IN GATA2 DEFICIENCY

EHA Library, Pauline Enfedaque, 4208301

A NEW MURINE CMML-LIKE MODEL: INDUCIBLE HSC-SPECIFIC UTX DELETION MIMICS KEY DISEASE FEATURES

EHA Library, Iryna Kovtun, 4208303

DIAGNOSTIC UTILITY OF B-CELL IMMUNOPHENOTYPING IN UNEXPLAINED CYTOPENIA

EHA Library, Catherine Cargo, 4208304

SINGLE-CELL INSIGHTS INTO THE DIFFERENTIATION SKEWING IN AML USING BLOOD-FORMING GASTRULOIDS.

EHA Library, Robel Tesfaye, 4208308

HYPOMETHYLATING AGENTS WITH OR WITHOUT VENETOCLAX IN TREATMENT-NAÏVE MYELODYSPLASTIC SYNDROMES WITH EXCESS BLASTS: RESULTS FROM A LARGE RETROSPECTIVE COHORT

EHA Library, Alex Bataller, 4208312

SEQUENTIAL THERAPY WITH DECITABINE AND AN XPO-1 INHIBITOR FOLLOWED BY ALLO-HSCT IN PATIENTS WITH MYELODYSPLASTIC NEOPLASM WITH BIALLELIC TP53 INACTIVATION : A PRELIMINARY CASE SERIES.

EHA Library, yanling Ren, 4208316

IMPACT OF VENETOCLAX BRIDGING ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN ADVANCED MYELODYSPLASTIC NEOPLASMS

EHA Library, Yu Wang, 4208317

HETROMBOPAG FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE SINGLE-CENTER STUDY

EHA Library, Rong Fu, 4208318

CLINICAL AND SURVIVAL IMPACT OF PRIOR IMMUNE AND ONCOLOGIC EXPOSURES IN ZRSR2-MUTATED MYELOID NEOPLASMS AND CCUS

EHA Library, Aref Al-Kali, 4208319

COMPARATIVE PROGNOSTIC PERFORMANCE OF SIX RISK SCORES AND EXPLORATORY INFLAMMATORY INDICES IN A REAL-WORLD CHRONIC MYELOMONOCYTIC LEUKEMIA COHORT

EHA Library, Tomas Rivero Equiza, 4208321

EVALUATING THE PROGNOSTIC SIGNIFICANCE OF MARROW COMPLETE REMISSION (MCR) IN HIGHER-RISK MDS: A META-REGRESSIVE ASSESSMENT OF SURROGATE ENDPOINT VALIDITY

EHA Library, Luis E. Aguirre, 4208323

IPSS-M OUTPERFORMS IPSS-R IN PREDICTING TIME TO TRANSFUSION DEPENDENCY IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Federica Pilo, 4208324

OUTCOMES OF PATIENTS DIAGNOSED WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA FOLLOWING SOLID ORGAN TRANSPLANTATION

EHA Library, Charan Vegivinti, 4208325

THERAPY-RELATED MYELOID NEOPLASMS FOLLOWING TREATMENT FOR PRIMARY HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Andrea Lattanzi, 4208329

CHARACTERIZATION OF ALN-CFB, AN INVESTIGATIONAL SIRNA TARGETING HEPATIC COMPLEMENT FACTOR B, IN NON-HUMAN PRIMATES AND CFB-HUMANIZED MICE

EHA Library, Kishor Devalaraja-Narashimha, 4208330

BONE MARROW BIOPSIES AND PLASMA REVEAL A DISRUPTED ANGIOGENIC LANDSCAPE IN SHWACHMAN–DIAMOND SYNDROME PATIENTS

EHA Library, Jennifer Romagnoli, 4208335

A HOMOZYGOUS LOSS-OF-FUNCTION MUTATION IN ARHGAP25 AS A NOVEL MECHANISM FOR CONGENITAL NEUTROPENIA

EHA Library, Maksim Klimiankou, 4208337

EFFICACY AND SAFETY OF SWITCHING TO ORAL HSK39297 MONOTHERAPY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA DESPITE ANTI-C5 THERAPY: A PHASE 3 STUDY (HSK39297-302)

EHA Library, Gaixiang Xu, 4208338

ORAL MY008211A DEMONSTRATES SUPERIOR EFFICACY VERSUS ECULIZUMAB IN COMPLEMENT INHIBITOR–NAÏVE CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Fengkui Zhang, 4208339

IPTACOPAN DEMONSTRATES SUSTAINED EFFICACY AND SAFETY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UP TO 4 YEARS OF FOLLOW-UP IN PATIENTS FROM APPLY, APPOINT AND ROLL-OVER EXTENSION PROGRAM

EHA Library, Régis Peffault de Latour, 4208340

HEMATOLOGIC MANIFESTATIONS OF NON-TINF2 AUTOSOMAL DOMINANT TELOMERE BIOLOGY DISORDERS

EHA Library, Emma Groarke, 4208341

ROMIPLOSTIM IN CHEMORADIOTHERAPY-ASSOCIATED APLASTIC ANAEMIA: A PROSPECTIVE SINGLE-ARM STUDY

EHA Library, qi wang, 4208342

BEYOND HEMATOLOGIC RESPONSE: SUSTAINED DEEP REMISSIONS AND FAVORABLE SAFETY WITH EXTENDED TPO-RA PLUS ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE AS FIRST-LINE THERAPY FOR SEVERE APLASTIC ANEMIA

EHA Library, Jingnan Sun, 4208343

BONE MARROW FEATURES AND CLINICAL OUTCOMES IN ELANE-ASSOCIATED CONGENITAL NEUTROPENIA: A NAPAAC/SCNIR STUDY

EHA Library, Helen Reed, 4208344

MOMELOTINIB IN VEXAS SYNDROME: A PRELIMINARY REPORT EVALUATION OF SAFETY AND EFFECTIVENESS

EHA Library, Elisa Diral, 4208345

REAL-WORLD HEMOGLOBIN PROFILES AND TRANSFUSION BURDEN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING COMPLEMENT INHIBITORS: A US CLAIMS ANALYSIS

EHA Library, Carlos de Castro, 4208348

LONG-TERM HEMATOLOGIC CONTROL AND SAFETY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH IPTACOPAN: 6-YEAR FOLLOW-UP FROM PHASE 2 STUDIES AND ROLL-OVER EXTENSION PROGRAM

EHA Library, Antonio M. Risitano, 4208349

MANAGEMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH IPTACOPAN

EHA Library, Isla Storey, 4208355

INDIVIDUALS HETEROZYGOUS FOR TERT P.ASP684GLY OR P.ARG774* ARE AT RISK OF TELOMERE BIOLOGY DISORDER

EHA Library, Tuulia Räisänen, 4208357

REAL-WORLD BASELINE CHARACTERISTICS OF PATIENTS INITIATING RAVULIZUMAB FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INSIGHTS FROM THE POLISH MULTICENTER OBSERVATIONAL STUDY (PNH RECORD)

EHA Library, Agnieszka Piekarska, 4208358

A PROSPECTIVE RANDOMIZED CONTROLLED STUDY OF RAPID OR SLOW CYCLOSPORIN A TAPERING REGIMENS IN ACQUIRED PURE RED CELL APLASIA

EHA Library, Guangsheng He, 4208359

ORAL MY008211A MONOTHERAPY ACHIEVES TRANSFUSION AVOIDANCE AND HEMOGLOBIN NORMALIZATION IN CHINESE PNH PATIENTS WITH RESIDUAL ANEMIA DESPITE C5 INHIBITION

EHA Library, Bing Han, 4208360

REDUCED DOSE OF GLUCOCORTICOIDS FOR PROPHYLAXIS OF SERUM SICKNESS IN APLASTIC ANEMIA POST ANTI-HUMAN T-LYMPHOCYTE GLOBULIN (ATG) TREATMENT: A RANDOMIZED TRIAL

EHA Library, Guangsheng He, 4208363

3-YEAR EFFICACY AND SAFETY OF CROVALIMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WHO SWITCHED FROM RAVULIZUMAB: LONG-TERM DATA FROM THE PHASE III COMMODORE 1 TRIAL

EHA Library, Yasutaka Ueda, 4208367

TEMPI SYNDROME PATIENT MONOCLONAL ANTIBODIES ARE PATHOGENIC DRIVERS OF ERYTHROPOIETIN PRODUCTION

EHA Library, David Sykes, 4208368

DUAL BTK AND BCL-2 INHIBITION DISMANTLES CXCR4 MUTATION–DRIVEN RESISTANCE IN WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Eleni Kalafati, 4208369

CIRCULATING TUMOR CELLS AND PLASMA MYD88 ΜAF AS PROGNOSTIC MARKERS FOR STAGING AND IBRUTINIB RESPONSE IN WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Tina Bagratuni, 4208371

CHROMATIN-DRIVEN TRANSCRIPTIONAL REPROGRAMMING SHAPES DISEASE EVOLUTION FROM MGUS TO MULTIPLE MYELOMA

EHA Library, Raghad Shuwaikan, 4208373

TUMOR-SPECIFIC IFNΒ GENE THERAPY ENABLES SYSTEMIC ERADICATION OF MULTIPLE MYELOMA

EHA Library, Eleni Kalafati, 4208374

HIGH-RISK GENOMIC FEATURES PREDICTING EXTRAMEDULLARY PROGRESSION IN MULTIPLE MYELOMA WITH PARASKELETAL PLASMACYTOMAS

EHA Library, Martin Stork, 4208376

LOSS OF LET-7C INCURRED BY PROMOTER HYPERMETHYLATION DRIVES MM DEVELOPMENT

EHA Library, Yonghuai Feng, 4208378

INTEGRATED SINGLE-CELL AND IMMUNE PROFILING IDENTIFIES DETERMINANTS OF MRD OUTCOME IN MULTIPLE MYELOMA

EHA Library, Anna Maria Corsale, 4208379

RISK-STRATIFIED PATIENT SELECTION IN MULTIPLE MYELOMA FOR FRONTLINE TREATMENT DECISION-MAKING BASED ON A TRANSCRIPTOMIC CLASSIFIER

EHA Library, Nikita Kotlov, 4208381

PERIPHERAL BLOOD CIRCULATING MYELOMA CELLS AS A REAL-TIME, NONINVASIVE SURROGATE FOR BONE MARROW MRD AFTER CELLULAR THERAPY AND AUTOLOGOUS TRANSPLANT

EHA Library, Ehsan Malek, 4208383

TARGETING THE DNA DAMAGE RESPONSE IN DORMANT MYELOMA CELLS

EHA Library, Abigail Foston, 4208386

TRANSCRIPTOMIC PROFILING OF MULTIPLE MYELOMA REVEALS COMMON AND TREATMENT SPECIFIC MOLECULAR SIGNATURES OF RELAPSE AND DRUG RESISTANCE FOLLOWING DARATUMUMAB, PI AND IMID THERAPY

EHA Library, Eleni Kalafati, 4208387

EXPLORING THE CELL-FREE TRANSCRIPTOME AS A BIOMARKER SOURCE IN IGM GAMMOPATHIES: AN ANALYSIS FROM THE “BIO-WM” TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

EHA Library, Philippe Decruyenaere, 4208388